/Boston%20Scientific%20Corp_%20logo%20on%20iPad-%20by%20Kate%20Krav-Rude%20via%20Shutterstock.jpg)
Valued at a market cap of $134.1 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties. The Marlborough, Massachusetts-based company's products are designed to improve the quality of patient care in areas such as cardiology, electrophysiology, endoscopy, urology, and neuromodulation. It is scheduled to announce its fiscal Q1 earnings for 2025 before the market opens on Wednesday, Apr. 23.
Ahead of this event, analysts expect this healthcare giant to report a profit of $0.67 per share, up 19.6% from $0.56 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street's earnings estimates in each of the last four quarters. In Q4 2024, BSX’s EPS of $0.70 exceeded the forecasted figure by 7.7%.
